FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890250608> ?p ?o ?g. }

• W2890250608 endingPage "65" @default.
• W2890250608 startingPage "55" @default.
• W2890250608 abstract "Antigenic stimulation is considered as a possible trigger of neoplastic transformation in chronic lymphocytic leukemia (CLL). B-cell receptor plays a key role in the interactions between the microenvironment and leukemic cells; however, an important role has also been attributed to Toll-like receptors (TLRs). It is believed that disorders of TLR expression may play a part in the pathogenesis of CLL. In this study, we investigated the potential role of TLR2 in CLL by analyzing its expression on leukemic B cells in correlation with clinical and laboratory parameters characterizing disease activity and patients' immune status. We assessed the frequencies of TLR2+/CD19+ cells by the flow cytometry method in peripheral blood of 119 patients with CLL. The percentage of TLR2+/CD19+ cells was significantly lower in patients with CLL as compared to the healthy volunteers. There was also a lower percentage of TLR2+/CD19+ cells in CLL patients with poor prognostic factors, such as ZAP70 and/or CD38 expression, 17p and/or 11q deletion. On the other hand, among patients with del(13q14) associated with favorable prognosis, the percentage of TLR2+/CD19+ cells was higher than among those with del(11q22) and/or del(17p13) as well as in the control group. We found an association between low percentage of CD19+/CD5+/TLR2+ cells and shorter time to treatment. We also demonstrated the relationship between low percentage of CD19+/CD5+ TLR2-positive and overall survival (OS) of CLL patients. CLL patients with a proportion of 1.6% TLR2-positive B CD5+ cells (according to the receiver operating characteristic curve analysis) or more had a longer time to treatment and longer OS than the group with a lower percentage of TLR2 positive cells. To sum up, the results of the study suggest that low TLR2 expression is associated with poor prognosis in CLL patients. The monitoring of CD19+/CD5+/TLR2+ cells number may provide useful information on disease activity. Level of TLR2 expression on leukemic B cells may be an important factor of immunological dysfunction for patients with CLL. Our study suggests that TLR2 could becomes potential biological markers for the clinical outcome in patients with CLL." @default.
• W2890250608 created "2018-09-27" @default.
• W2890250608 creator A5033354752 @default.
• W2890250608 creator A5056338889 @default.
• W2890250608 creator A5057017325 @default.
• W2890250608 creator A5063491781 @default.
• W2890250608 creator A5077345399 @default.
• W2890250608 creator A5085299270 @default.
• W2890250608 creator A5087210110 @default.
• W2890250608 date "2018-09-08" @default.
• W2890250608 modified "2023-10-18" @default.
• W2890250608 title "TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia" @default.
• W2890250608 cites W154103547 @default.
• W2890250608 cites W1627009127 @default.
• W2890250608 cites W1814084293 @default.
• W2890250608 cites W1994942139 @default.
• W2890250608 cites W1995653973 @default.
• W2890250608 cites W1999578911 @default.
• W2890250608 cites W2000902524 @default.
• W2890250608 cites W2006363533 @default.
• W2890250608 cites W2017614316 @default.
• W2890250608 cites W2021230504 @default.
• W2890250608 cites W2048842878 @default.
• W2890250608 cites W2058801589 @default.
• W2890250608 cites W2062581231 @default.
• W2890250608 cites W2080766669 @default.
• W2890250608 cites W2098084836 @default.
• W2890250608 cites W2098166849 @default.
• W2890250608 cites W2101037187 @default.
• W2890250608 cites W2106064762 @default.
• W2890250608 cites W2115185894 @default.
• W2890250608 cites W2116911597 @default.
• W2890250608 cites W2119707195 @default.
• W2890250608 cites W2140499692 @default.
• W2890250608 cites W2150745128 @default.
• W2890250608 cites W2153689296 @default.
• W2890250608 cites W2288473202 @default.
• W2890250608 cites W2318933236 @default.
• W2890250608 cites W2342038428 @default.
• W2890250608 cites W2420202036 @default.
• W2890250608 cites W2578141683 @default.
• W2890250608 doi "https://doi.org/10.1007/s00005-018-0523-9" @default.
• W2890250608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6433797" @default.
• W2890250608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30196472" @default.
• W2890250608 hasPublicationYear "2018" @default.
• W2890250608 type Work @default.
• W2890250608 sameAs 2890250608 @default.
• W2890250608 citedByCount "5" @default.
• W2890250608 countsByYear W28902506082020 @default.
• W2890250608 countsByYear W28902506082022 @default.
• W2890250608 countsByYear W28902506082023 @default.
• W2890250608 crossrefType "journal-article" @default.
• W2890250608 hasAuthorship W2890250608A5033354752 @default.
• W2890250608 hasAuthorship W2890250608A5056338889 @default.
• W2890250608 hasAuthorship W2890250608A5057017325 @default.
• W2890250608 hasAuthorship W2890250608A5063491781 @default.
• W2890250608 hasAuthorship W2890250608A5077345399 @default.
• W2890250608 hasAuthorship W2890250608A5085299270 @default.
• W2890250608 hasAuthorship W2890250608A5087210110 @default.
• W2890250608 hasBestOaLocation W28902506081 @default.
• W2890250608 hasConcept C10205521 @default.
• W2890250608 hasConcept C113067387 @default.
• W2890250608 hasConcept C136449434 @default.
• W2890250608 hasConcept C147483822 @default.
• W2890250608 hasConcept C159912055 @default.
• W2890250608 hasConcept C18031839 @default.
• W2890250608 hasConcept C203014093 @default.
• W2890250608 hasConcept C2776709828 @default.
• W2890250608 hasConcept C2777938653 @default.
• W2890250608 hasConcept C2778461978 @default.
• W2890250608 hasConcept C2778957590 @default.
• W2890250608 hasConcept C2781236682 @default.
• W2890250608 hasConcept C28328180 @default.
• W2890250608 hasConcept C502942594 @default.
• W2890250608 hasConcept C553184892 @default.
• W2890250608 hasConcept C71924100 @default.
• W2890250608 hasConcept C86803240 @default.
• W2890250608 hasConcept C8891405 @default.
• W2890250608 hasConcept C95444343 @default.
• W2890250608 hasConceptScore W2890250608C10205521 @default.
• W2890250608 hasConceptScore W2890250608C113067387 @default.
• W2890250608 hasConceptScore W2890250608C136449434 @default.
• W2890250608 hasConceptScore W2890250608C147483822 @default.
• W2890250608 hasConceptScore W2890250608C159912055 @default.
• W2890250608 hasConceptScore W2890250608C18031839 @default.
• W2890250608 hasConceptScore W2890250608C203014093 @default.
• W2890250608 hasConceptScore W2890250608C2776709828 @default.
• W2890250608 hasConceptScore W2890250608C2777938653 @default.
• W2890250608 hasConceptScore W2890250608C2778461978 @default.
• W2890250608 hasConceptScore W2890250608C2778957590 @default.
• W2890250608 hasConceptScore W2890250608C2781236682 @default.
• W2890250608 hasConceptScore W2890250608C28328180 @default.
• W2890250608 hasConceptScore W2890250608C502942594 @default.
• W2890250608 hasConceptScore W2890250608C553184892 @default.
• W2890250608 hasConceptScore W2890250608C71924100 @default.
• W2890250608 hasConceptScore W2890250608C86803240 @default.
• W2890250608 hasConceptScore W2890250608C8891405 @default.
• W2890250608 hasConceptScore W2890250608C95444343 @default.

• next